早期炎症性关节炎患者的COVID-19住院与死亡:英国全国队列研究结果
基于英国国家早期炎症性关节炎审计(NEIAA)观察性队列,纳入2020年2月至2021年5月的14127例早期炎症性关节炎患者,通过NHS Digital联动记录COVID-19住院与死亡结局,采用Cox比例风险模型计算校正混杂因素后的风险比。结果显示患者特征(年龄、性别、合并症、既往吸烟)与COVID-19不良结局的关联强于初始治疗策略。
要点
- 14127例早期炎症性关节炎患者中,COVID-19住院143例、死亡47例。
- 住院发生率为每100人年0.93(95%CI 0.79,1.10),死亡为0.30(95%CI 0.23,0.40)。
- 初始治疗策略与COVID-19结局的关联在校正混杂因素后均未达统计学显著。
核心结论
- 在早期炎症性关节炎患者中,患者特征与COVID-19的关联强于初始治疗策略。
研究设计与样本
- NEIAA为观察性队列,纳入2020年2月至2021年5月的成人早期炎症性关节炎患者。
- 通过NHS Digital联动确定COVID-19住院与死亡结局,采用Cox比例风险模型计算风险比并校正混杂因素。
主要发现
- 14127例早期炎症性关节炎患者中,COVID-19住院143例、死亡47例。
- 住院发生率为每100人年0.93(95%CI 0.79,1.10),死亡发生率为每100人年0.30(95%CI 0.23,0.40)。
- 年龄增加、男性、合并症和既往吸烟与更差的COVID-19结局风险增加相关。
- 基线DAS28较高与COVID-19住院(校正后风险比1.10;95%CI 0.97,1.24)及死亡(校正后风险比1.11;95%CI 0.90,1.37)均无关联。
- 血清阳性与两种结局均无关联,患者报告指标中症状负担较高预测更差的COVID-19结局。
关键数值与推荐
- 未校正模型中,糖皮质激素与COVID-19死亡相关(风险比2.29;95%CI 1.02,5.13)。
- 未校正模型中,柳氮磺吡啶单药治疗与COVID-19住院相关(风险比1.92;95%CI 1.04,3.56)。
- 校正模型中,糖皮质激素和柳氮磺吡啶的关联均未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出一个重要局限性为未观察治疗随时间的变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the risks and predictors of coronavirus disease 2019 (COVID-19) hospitalization and mortality among patients with early inflammatory arthritis (EIA), recruited to the National Early Inflammatory Arthritis Audit (NEIAA). METHODS: NEIAA is an observational cohort. We included adults with EIA from Feb 2020 to May 2021. Outcomes of interest were hospitalization and death due to COVID-19, using NHS Digital linkage. Cox proportional hazards were used to calculate hazard ratios for outcomes according to initial treatment strategy, with adjustment for confounders. RESULTS: From 14 127 patients with EIA, there were 143 hospitalizations and 47 deaths due to COVID-19, with incidence rates per 100 person-years of 0.93 (95% CI 0.79, 1.10) for hospitalization and 0.30 (95% CI 0.23, 0.40) for death. Increasing age, male gender, comorbidities and ex-smoking were associated with increased risk of worse COVID-19 outcomes. Higher baseline DAS28 was not associated with COVID-19 admissions [confounder adjusted hazard ratio (aHR) 1.10; 95% CI 0.97, 1.24] or mortality (aHR 1.11; 95% CI 0.90, 1.37). Seropositivity was not associated with either outcome. Higher symptom burden on patient-reported measures predicted worse COVID-19 outcomes. In unadjusted models, CS associated with COVID-19 death (HR 2.29; 95% CI 1.02, 5.13), and SSZ monotherapy associated with COVID-19 admission (HR 1.92; 95% CI 1.04, 3.56). In adjusted models, associations for CS and SSZ were not statistically significant. CONCLUSION: Patient characteristics have stronger associations with COVID-19 than the initial treatment strategy in patients with EIA. An important limitation is that we have not looked at treatment changes over time.
引用
- Adas MA, Russell MD, Cook E, et al. COVID-19 admissions and mortality in patients with early inflammatory arthritis: results from a UK national cohort. Rheumatology (Oxford). 2023. PMID: 36645234. doi:10.1093/rheumatology/kead018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。